DRREDDY · NSE
Dr. Reddy's Laboratories Limited
₹1,390.2
-0.76% (-₹10.7)
Prev. close
₹1,400.9
Volume
8,30,660
Delivery %
49.2%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
3 analyst stances · last 90 days · one per analyst
Trackable
3 · 3 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Dr Reddy's Lab, recommending a buy at ₹1243 with a stop loss at ₹1180 and a target of ₹1370. The stock shows …” | Sachin GuptaChoice Equity Broking | Dr Reddy's Laboratories Ltd | HIT | |
| “Upgraded Dr. Reddy's Laboratories to 'buy' from 'sell' with a target price of ₹1,450, implying an 18.8% upside. This upg…” | Citi AnalysisCitigroup Inc. | Dr. Reddy's Laboratories | PENDING | |
| “Bullish on Dr Reddy’s Labs, recommending a buy at ₹1165 with a target of ₹1290 and a stop loss at ₹1100. The stock is at…” | Sumeet BagadiaChoice Equity Broking | Dr Reddy's Laboratories | HIT | |
| “Bullish on Dr. Reddy's Laboratories for the short term, with a target price of ₹1,480 and a stop loss at ₹1,300. The sto…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Dr. Reddy's Laboratories | MISS | |
| “Nomura maintains a 'buy' rating on Dr. Reddy's Laboratories with a price target of ₹1,740, implying a 29% upside. The br…” | Nomura AnalysisNomura Global Markets Research | Dr. Reddy's Laboratories | PENDING | |
| “Bullish on Dr. Reddy’s Laboratories Ltd, recommending a buy at ₹1,283.50 with a target of ₹1,368 and a stop loss at ₹1,2…” | Ankush BajajIndependent | Dr. Reddy's Laboratories Ltd | MISS | |
| “Recommends buying Dr Reddy's Laboratories at ₹1258, targeting ₹1350 with a stop loss at ₹1210. The stock shows improving…” | Sumeet BagadiaChoice Equity Broking | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Recommends buying Dr. Reddy’s Labs for the short term, with a target of ₹1,250 / ₹1,265 and a stop-loss at ₹1,185. The s…” | Prashanth TapseMehta Equities Ltd | Dr. Reddy's Laboratories Ltd. | HIT | |
| “Maintained 'Buy' rating on Dr Reddy’s Laboratories with a target price of Rs 1,588, despite revenue and EBITDA being bel…” | Elara Capital AnalysisElara Capital | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Maintained 'Buy' rating on Dr Reddy’s Laboratories with a December 2026 target price of Rs 1,650, noting that low Street…” | Nomura AnalysisNomura Global Markets Research | Dr Reddy's Laboratories Ltd. | PENDING | |
| “Recommends buying Dr Reddy's Laboratories at ₹1,285, targeting ₹1,320, with a stop loss at ₹1,260.” | Vaishali ParekhPrabhudas Lilladher | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Bullish on Dr Reddy's in the pharma space, observing a base formation around its 200 DMA and a double bottom breakout, w…” | Rajesh BhosaleIndependent | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Recommends buying Dr Reddy's Laboratories at ₹1255.90, targeting ₹1340 with a stop loss at ₹1210. The stock is consolida…” | Sumeet BagadiaChoice Equity Broking | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Recommends buying Dr Reddy's Laboratories in the ₹1260-1265 range, with a stop loss at ₹1230 and a target price of ₹1300…” | Ganesh DongreAnand Rathi | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Bullish on Dr. Reddy's Laboratories for the next one to two weeks, targeting ₹1,410 with a stop loss at ₹1,250. The stoc…” | Ajit MishraReligare Broking | Dr. Reddy's Laboratories | MISS | |
| “Short-term traders can consider buying Dr. Reddy’s Laboratories, targeting Rs 1,360 within 1-2 months. The stock broke o…” | ETMarkets AnalysisETMarkets.com | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Recommends buying Dr Reddy's Laboratories at ₹1268, targeting ₹1360 (and potentially ₹1380 near-term) with a stop loss a…” | Sumeet BagadiaChoice Equity Broking | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Bullish on Dr Reddy's Laboratories Ltd with an initial upside target of ₹1,350-1,360. The stock has given a bullish flag…” | Sagar DoshiNuvama Professional Clients Group | Dr. Reddy's Laboratories Ltd. | HIT | |
| “Recommends buying Dr Reddy's Laboratories at ₹1211.40, targeting ₹1330 with a stop loss at ₹1150 for the short to medium…” | Sumeet BagadiaChoice Equity Broking | Dr. Reddy's Laboratories | MISS | |
| “Bearish on Dr. Reddy's Laboratories with a target of ₹1,120. The call implies an expectation of price decline for the st…” | Deven ChokseyIndependent | Dr. Reddy's Laboratories | MISS | |
| “Bullish on Dr Reddy's Labs, which has seen a short-term consolidation breakout and a falling trendline breakout on the d…” | Vatsal BhuvaLKP Securities | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Nuvama maintains a 'Buy' rating on Dr. Reddy’s Laboratories with a target price of Rs 1,486, implying a 19% upside from …” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Dr. Reddy's Laboratories | MISS | |
| “Cautious on Dr. Reddy's Laboratories, assigning a target price of ₹1,100. Q1 results missed estimates due to lower US sa…” | Jefferies AnalysisJefferies | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Recommends buying Dr Reddy’s Laboratories with a target of ₹1350 and a stop loss at ₹1267, suggesting a short-term bulli…” | Sharan LillaneyIndependent | Dr. Reddy's Laboratories | MISS | |
| “Bullish on Dr Reddy’s Laboratories, recommending a buy with a target price of ₹1,405 and a stop loss at ₹1,290. The stoc…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Recommends buying Dr. Reddy’s Labs in the short term, targeting ₹1,400 / ₹1,430 with a stop loss at ₹1,315. The stock is…” | Prashanth TapseMehta Equities Ltd | Dr. Reddy's Laboratories Ltd | MISS | |
| “Recommends buying Dr Reddy's Laboratories at around ₹1348.80, with a stop loss at ₹1300 for a target price of ₹1443. The…” | Sumeet BagadiaChoice Equity Broking | Dr. Reddy's Laboratories Ltd | MISS | |
| “Bullish on Dr Reddy’s Laboratories Ltd, recommending a buy with a target of ₹1265 and a stop loss at ₹1200 for a short-t…” | Jatin GediaSharekhan by BNP Paribas | Dr. Reddy's Laboratories Ltd | HIT | |
| “Maintains a Buy rating on Dr. Reddy's Laboratories, lowering the target price to ₹1,418. The brokerage anticipates stron…” | JM Financial AnalysisJM Financial Institutional Securities | Dr. Reddy's Laboratories | MISS | |
| “Recommends buying Dr. Reddy's Laboratories around ₹1200.50, setting a stop-loss at ₹1158 for a target price of ₹1284. Th…” | Sumeet BagadiaChoice Equity Broking | Dr. Reddy's Laboratories Ltd | MISS | |
| “Bullish on Dr Reddy’s, recommending a buy at ₹1144 with a stop loss at ₹1090 and a target of ₹1200. The stock is perform…” | Aditya AroraAdlytick | Dr. Reddy's Laboratories Ltd. | HIT | |
| “Recommends buying Dr Reddy's Laboratories at ₹1109, targeting ₹1160, with a stop loss at ₹1080.” | Vaishali ParekhPrabhudas Lilladher | Dr. Reddy's Laboratories Ltd. | HIT | |
| “Bullish on Dr. Reddy’s Laboratories with a target of ₹1,255 and a stop loss at ₹1,200 for a short-term trading horizon.” | Jatin GediaSharekhan by BNP Paribas | Dr. Reddy's Laboratories | MISS | |
| “Bearish on Dr. Reddy's Laboratories, recommending a 'Sell' with a target price of ₹1,150. The call implies an expectatio…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Dr. Reddy's Laboratories | HIT | |
| “Maintained a 'BUY' rating on Dr Reddy's Laboratories with a target price of ₹1,723, despite tepid US sales in Q3 due to …” | JM Financial AnalysisJM Financial Institutional Securities | Dr Reddy's Laboratories Ltd | MISS | |
| “Maintained an 'Underperform' rating on Dr Reddy's Laboratories, revising the price target to ₹1,170. The weakness in cor…” | Jefferies AnalysisJefferies | Dr. Reddy's Laboratories Ltd. | HIT | |
| “Maintained a 'Buy' rating on Dr Reddy's Laboratories with a revised target price of ₹1,533 (down from ₹1,553). Despite a…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Maintained an 'Underperform' rating on Dr Reddy's shares, revising the target price to ₹1,170 from ₹1,210. The call is d…” | Jefferies AnalysisJefferies | Dr. Reddy's Laboratories Ltd. | HIT | |
| “Downgraded Dr Reddy's Laboratories to 'underperform' and reduced its target price to ₹1090 (from ₹1140), indicating a 15…” | CLSA AnalysisCLSA | Dr. Reddy's Laboratories Ltd. | HIT | |
| “Bullish on Dr. Reddy's Laboratories, recommending a buy at ₹1295 with a stop loss at ₹1260 for a target price of ₹1360. …” | Ganesh DongreAnand Rathi | Dr. Reddy's Laboratories Ltd | MISS | |
| “Bearish on Dr. Reddy's Laboratories Ltd, recommending a sell below ₹1,285 with a stop loss at ₹1,305 and a target of ₹1,…” | Raja VenkatramanNeoTrader | Dr. Reddy's Laboratories Ltd | HIT | |
| “Bearish on Dr. Reddy's Laboratories, recommending a sell below ₹1,285 with a stop loss at ₹1,305 and a target of ₹1,225.…” | Raja VenkatramanNeoTrader | Dr. Reddy's Laboratories Ltd | HIT | |
| “JM Financial recommends buying Dr Reddy's Laboratories with a target price of ₹1,737, against a current price of ₹1,325.…” | JM Financial AnalysisJM Financial Institutional Securities | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Bullish on Dr Reddy’s Laboratories, recommending a buy with a target of Rs 1450 and a stop loss at Rs 1320 for traders w…” | Nooresh MeraniIndependent | Dr. Reddy's Laboratories | MISS | |
| “Upgraded Dr Reddy's to 'Buy' from 'Reduce' with a target price of ₹1,553, valuing the stock at 24x FY27E EPS. The broker…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Dr. Reddy's Laboratories Ltd. | MISS | |
| “Upgraded Dr. Reddy's Laboratories to 'buy' with a target price of ₹1,553, implying a 15% potential upside. The brokerage…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Dr. Reddy's Laboratories | MISS | |
| “Bullish on Dr Reddy’s Laboratories for the short-term, recommending a buy with a target price of Rs 1422 and a stop loss…” | Dharmesh ShahICICI Securities | Dr. Reddy's Laboratories | MISS | |
| “Upgraded Dr. Reddy's Laboratories to 'Buy' with a target price of ₹1,500 per share.” | Nomura AnalysisNomura Global Markets Research | Dr. Reddy's Laboratories | PENDING | |
| “Emkay Global Financial recommends selling Dr. Reddy's Laboratories with a target price of ₹1,070.” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Dr. Reddy's Laboratories | PENDING | |
| “Recommends buying Dr Reddy’s Laboratories with a target of ₹7100 and a stop loss at ₹6650 for short-term traders.” | Nooresh MeraniIndependent | Dr. Reddy's Laboratories | PENDING | |
| “Bullish on Dr Reddy’s Laboratories, recommending a buy with a target of Rs 7100 and a stop loss at Rs 6650.” | Nooresh MeraniIndependent | Dr. Reddy's Laboratories | PENDING |
Market commentary · 15 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Motilal Oswal lowered Dr Reddy's Laboratories' FY27 EPS estimate by 19% to ₹37.2 from ₹45.9, anticipating a 37% decline …” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Dr Reddy's Laboratories | — | |
| “Bearish on Dr Reddy's Laboratories after its GLP-1 drug launch faced regulatory hurdles in Canada, calling it a 'major s…” | Narendra SolankiAnand Rathi Shares & Stock Brokers | Dr. Reddy's Laboratories Ltd. | — | |
| “Maintained 'Buy' rating on Dr Reddy’s Laboratories, lowering the target price slightly to Rs 1,475 from Rs 1,486. Q2 rev…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Dr. Reddy's Laboratories Ltd. | — | |
| “Bullish on Dr. Reddy’s. The stock is taking support near its 20-day moving average and 89 EMA on the daily chart, which …” | Sneha SethAngel One | Dr. Reddy's Laboratories Ltd. | — | |
| “Neutral on Dr. Reddy's Laboratories, with a target price of ₹1,274, indicating no major upside from current levels. The …” | Choice Institutional Equities AnalysisChoice Institutional Equities | Dr. Reddy's Laboratories | — | |
| “Maintains a neutral rating on Dr. Reddy's Laboratories. While the semaglutide opportunity in Canada and other markets is…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Dr. Reddy's Laboratories | — | |
| “Projects Dr Reddy's PAT to grow 14% YoY and QoQ to ₹1,659 crore, with revenue rising 19% YoY to ₹9,094 crore, driven by …” | Phillip Capital AnalysisPhillip Capital | Dr. Reddy's Laboratories Ltd. | — | |
| “Bearish on Dr. Reddy's, trimming its target price and seeing a 26% downside for the shares. This outlook suggests a sign…” | Citi AnalysisCitigroup Inc. | Dr. Reddy's Laboratories Ltd. | — | |
| “Sees over 30% upside in Dr. Reddy's Laboratories (DRL) over the next 12 months, citing attractive valuations and robust …” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Dr. Reddy's Laboratories | — | |
| “Dr. Reddy’s Laboratories is at highest risk among generic pharma companies from potential US tariffs, with approximately…” | Jefferies AnalysisJefferies | Dr. Reddy's Laboratories Ltd. | — | |
| “Maintained a 'Neutral' rating on Dr Reddy's Laboratories shares with a target price of ₹1,331. The base profit (excludin…” | DAM Capital AnalysisDAM Capital | Dr. Reddy's Laboratories Ltd. | — | |
| “Kotak Equities expects Dr. Reddy's North America base business (ex-Revlimid) sales to decline 4% QoQ to $303 million due…” | Kotak Institutional Equities AnalysisKotak Institutional Equities | Dr. Reddy's Laboratories Limited | — | |
| “Nuvama expects Dr. Reddy's revenue and EBITDA to grow by 17% and 13% YoY respectively, with EBITDA margins at 27.5% for …” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Dr. Reddy's | — | |
| “Centrum expects Dr. Reddy's US sales to grow 7% YoY (CC) to $430 million, primarily due to muted growth in Lenalidomide.…” | Centrum Broking AnalysisCentrum Broking | Dr. Reddy's Laboratories Ltd. | — | |
| “Maintains a positive bias on Dr Reddy's, observing a higher top, higher bottom structure after the stock tested beyond ₹…” | Rajesh BhosaleAngel One | Dr. Reddy's Laboratories Ltd. | — |
Fundamentals
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Erez Israeli M.B.A.
Headquarters
Hyderabad
Employees
27,527
Website
drreddys.comExchange
View on NSE ↗Key stats
Market cap
₹1.14 L Cr
P/E ratio (TTM)
40.6
Dividend yield
0.58%
EPS (TTM)
₹33.59
Beta (1Y · daily vs NIFTY 50)
0.47
Beta (5Y · monthly vs NIFTY 50)
0.41
Shares float
60.01 Cr
EPS · quarter ended Sept 2026
₹11.10
Upcoming earnings
21 Jan 2027
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹19,047.50 Cr | ₹21,545.20 Cr | ₹24,669.70 Cr | ₹28,011.10 Cr | ₹32,643.90 Cr | ₹33,700.20 Cr | |
EBITDA | ₹4,161.30 Cr | ₹4,252.10 Cr | ₹7,443.10 Cr | ₹8,827.40 Cr | ₹9,644.40 Cr | ₹7,916.00 Cr |
| ₹1,952.00 Cr | ₹2,182.00 Cr | ₹4,506.70 Cr | ₹5,577.90 Cr | ₹5,655.10 Cr | ₹4,285.00 Cr | |
Diluted EPS | ₹23.47 | ₹26.24 | ₹54.18 | ₹66.92 | ₹67.79 | ₹51.42 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹26,616.80 Cr | ₹29,746.90 Cr | ₹32,285.10 Cr | ₹38,780.00 Cr | ₹48,023.00 Cr | ₹56,577.00 Cr | |
| ₹3,030.80 Cr | ₹3,004.50 Cr | ₹608.20 Cr | ₹2,002.00 Cr | ₹4,676.60 Cr | ₹7,734.10 Cr | |
Stockholders' equity | ₹17,641.70 Cr | ₹19,212.40 Cr | ₹23,286.10 Cr | ₹28,254.00 Cr | ₹33,549.00 Cr | ₹37,892.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,570.30 Cr | ₹2,810.80 Cr | ₹5,888.00 Cr | ₹4,543.00 Cr | ₹4,643.00 Cr | ₹5,674.00 Cr | |
Investing cash flow | ₹-2,266.00 Cr | ₹-2,638.70 Cr | ₹-4,137.10 Cr | ₹-4,028.30 Cr | ₹-5,807.70 Cr | ₹-6,549.30 Cr |
| ₹-29.80 Cr | ₹-242.20 Cr | ₹-2,686.10 Cr | ₹-376.30 Cr | ₹1,891.10 Cr | ₹829.00 Cr | |
Capital expenditure | ₹-1,256.10 Cr | ₹-1,904.90 Cr | ₹-1,887.00 Cr | ₹-2,744.00 Cr | ₹-3,440.00 Cr | ₹-3,840.00 Cr |
End cash position | ₹1,482.90 Cr | ₹1,485.20 Cr | ₹577.90 Cr | ₹710.70 Cr | ₹1,459.30 Cr | ₹1,536.80 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 26.72% | 26.72% | 26.71% | 26.71% | 26.70% | 26.70% | 26.69% | 26.66% | 26.65% | 26.65% | 26.65% | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.63% | 26.64% |
| Public | 72.99% | 73.00% | 73.01% | 73.02% | 73.05% | 73.08% | 73.10% | 73.16% | 73.17% | 73.17% | 73.18% | 73.20% | 73.07% | 73.10% | 73.11% | 73.12% | 73.13% | 73.16% |
| Employee trusts | 0.29% | 0.28% | 0.28% | 0.27% | 0.25% | 0.22% | 0.21% | 0.18% | 0.18% | 0.17% | 0.17% | 0.16% | 0.29% | 0.26% | 0.25% | 0.25% | 0.24% | 0.20% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Lupin Limited | ₹92,244.53 Cr | ₹2,008.6 | 16.7 | 4.11 | 23.8% | 0.29 | +23.9% | +0.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.